2.65
-0.12(-4.33%)
Currency In USD
| Previous Close | 2.77 |
| Open | 3 |
| Day High | 3 |
| Day Low | 2.67 |
| 52-Week High | 8.32 |
| 52-Week Low | 0.87 |
| Volume | 1.46M |
| Average Volume | 1.06M |
| Market Cap | 114.42M |
| PE | -3.18 |
| EPS | -0.84 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 2.16 |
| Change | -0.1 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $3.91 as of August 19, 2025 at a share price of $2.67. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $87.25 as of August 19, 2025 at a share price of $2.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
GlobeNewswire Inc.
Jul 24, 2025 1:00 PM GMT
ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will pres
Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GlobeNewswire Inc.
Jul 22, 2025 12:45 PM GMT
Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina disea
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
GlobeNewswire Inc.
Jul 01, 2025 12:05 PM GMT
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver